



**Europäisches  
Patentamt**

**European  
Patent Office**

**Office européen  
des brevets**

22. 06. 2004

REC'D 27 JUL 2004

WIPO

PCT

**Bescheinigung**

**Certificate**

**Attestation**

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

**Patentanmeldung Nr. Patent application No. Demande de brevet n°**

03014020.6

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk





Anmeldung Nr:  
Application no.: 03014020.6  
Demande no:

Anmeldetag:  
Date of filing: 23.06.03  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

BioTech Tools S.A.  
rue de Ransbeek 230, Bât.5  
1120 Bruxelles  
BELGIQUE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se referer à la description.)

Epitope composition

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

A61K38/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL  
PT RO SE SI SK TR LI



### **Epitope composition**

The present invention relates to a pharmaceutical composition and the use of the pharmaceutical composition.

5

#### **Background of the invention**

There are a large number of severe diseases based on unwanted recognition of antigens by antibodies. These diseases include allergic reactions and autoim-  
10 mune diseases and antigen/antibody reactions are also responsible for graft rejections after transplantation.

Beside a large number of medicaments for suppression of the immune reaction or the symptoms of the diseases no satisfying causal therapy is available. De-  
15 spite a large number of experiments and studies, there is still a need for new pharmaceutical compositions.

WO 88/10120 discloses a method of treating a T-cell mediated autoimmune disease in animals by oral or enteral administration of autoantigens, fragments  
20 of autoantigens or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease.

US 6,312,711 discloses a pharmaceutical and/or food composition comprising at least one of the conformational or sequential epitopes of an antigenic structure  
25 related to graft rejection, allergic reaction or autoimmune reaction together with stress protein selected from the group of stress protein GroEL, GrpE, DnaK and DnaJ.

Pecquet et al., in Vaccine 18 (2000) 1196 to 1202, disclose the induction of oral  
30 tolerance in mice by entrapped B-lactoglobulin. As discussed in this article, controversial results have been obtained by different groups in connection with similar studies.

- 2 -

Aim of the invention

The aim of the present invention is to provide a novel pharmaceutical composition designed to modify the immune response of patients towards diseases associated with an allergic or autoimmune reaction or towards graft rejection.

A further aim was to provide a composition which produces reliable and reproducible results.

Another aim is to provide a method for treatment or prevention of graft rejection, allergic reaction or autoimmune disease.

Summary of the invention

In one embodiment of the invention, the invention provides a pharmaceutical composition for sublingual or enteric administration comprising at least one substance obtainable by hydrolysis of an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease.

Another embodiment of the invention is the use of the composition of the invention for the treatment or prevention of graft rejection, allergic reaction or autoimmune disease or for eliciting oral tolerance and/or the induction of cells that may produce immunosuppressive cytokines, more preferably TGF-beta and/or IL-4 and/or IL-10.

In a further embodiment, the invention provides a process for the preparation of the pharmaceutical composition of the invention comprising the steps of

- hydrolyzing an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease to obtain at least one substance
- formulating the at least one substance for enteric or sublingual administration

- 3 -

Detailed description of the invention

The present invention provides a pharmaceutical composition for sublingual or enteric administration comprising at least one substance obtainable by hydrolysis of an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease.

Graft rejection, allergic reaction or autoimmune diseases are hypersensitivity reactions of immediate or delayed type brought about by contact in particular with an allergen (this reaction can be immediate and specific (anaphylaxis, urticaria, etc.) or delayed over time) or autoimmune diseases and disorders of the immune system of immediate or delayed type associated with graft rejections of host against graft type and a graft against host type.

Autoimmune diseases or disorders are a state of immunization of an individual against his or her own constituents and the phenomenon of graft rejection is a state of immunization of an individual against foreign constituents brought into contact with the patients. Typical autoimmune diseases are inter alia Systemic Lupus erythematosus disease, Sjögren's disease, rheumatoid polyarthritis, as well as pathologies such as sarcoidosis and osteopenia, spondylarthritis, scleroderma, multiple sclerosis, amyotrophic lateral sclerosis, hyperthyroidism, Addison's disease, autoimmune hemolytic anemia, Crohn's disease, Goodpasture's syndrome, Graves' disease, Hashimoto's thyroiditis, idiopathic purpural hemorrhage, insulin-dependent diabetes, myasthenia, pemphigus vulgaris, pernicious anemia, poststreptococcal glomerulonephritis, psoriasis and spontaneous sterility.

The term "antigenic structure" covers macromolecules such as allergens made of peptides, lipids, polysaccharides and/or nucleic acids. Typical antigenic structures are inter alia insulin, thyroglobulin, thyroid peroxidase, type II collagen, gliadin, GAD65, proteolipid protein, S-antigen, acetylcholin receptor, haptenized colonic proteins, Interphotoreceptor retinoid binding protein, myelin basic pro-

- 4 -

tein, myelin oligodendrocyte glycoprotein, peripheral nerve P2, cytoplasmic TSH receptor, intrinsic factor, lens proteins, platelets, nucleoproteins such as histones, heat shock proteins, MHC I, MHC II, MHC-peptides complexes, milk allergens, venom allergens, egg allergens, weed allergens, grass allergens, tree  
5 allergens, shrub allergens, flower allergens, grain allergens, fungi allergens, fruit allergens, berry allergens, nut allergens, seed allergens, bean allergens fish allergens, shellfish allergens, meat allergens, spices allergens, insect allergens, mite allergens, animal allergens, animal dander allergens, allergens of Hevea brasiliensis, coagulation factors and blood group antigens.

10

According to the invention, the composition comprises at least one substance which is obtainable by hydrolysis of an antigenic structure, that is according to the invention not complete antigenic structure are used in the pharmaceutical composition but fragments thereof.

15

Such substances can either be prepared by hydrolysis but they can also be prepared by synthetic methods.

20

In case of an hydrolysis, the antigenic structure can be modified prior to hydrolysis either by physical e.g. heating, high mechanical pressure or by chemical methods e.g. reductive reagents (such as thioredoxin activated either by NADPH via NADP-thioredoxin-reductase or by dithiothreitol) oxidative reagents, alkylating reagents, urea, guanidinium chloride.

25

What is important according to the invention is that the pharmaceutical composition is prepared for sublingual or enteric administration.

30

"Sublingual administration" is a method wherein the substance is combined in a pharmaceutical formulation which allows absorption of the at least one substance in the mouth mucosa.

"Enteric administration" is a pharmaceutical formulation which protects the ac-



- 5 -

tive ingredient from absorption prior to entry into the intestine. Preferably absorption is effected in the ileum, duodenum or jejunum.

Especially suitable formulation includes coating with polymers, e.g. as sold under the trademark Eudragit®, commercially available from Degussa, Germany. Eudragid® polymers are suitable for solid oral formulations which are released in the intestine.

Without wishing to be bound to a theory, it is believed that former formulations of such antigenic structures were partially destroyed by the gastric juice. While this might have produced hydrolyzed fragments of the respective antigens, the amount of hydrolyzed peptides absorbed was highly dependent of the digestive activity of the patient and, therefore, it was highly variable.

Only with a pharmaceutical composition of the present invention, the composition can be produced with constant quality. By either sublingual or enteric administration, the amount of absorbed active ingredient can be tightly controlled.

It is important to identify the adequate amount for treatment or prevention of a respective diseases or disorders. Typical preferred amounts are in the range of 0.001 µg to 1,000 µg per dosage unit and it is preferred that the dosage unit is 0.01 µg or more. In a more preferred embodiment, the dosage unit is 0.1 µg or more and in a very preferred embodiment, it is 1 µg or more.

It is also important that the amount of active ingredient is not too high. It is preferred that the amount of the at least one substance is 100 µg or less, 50 µg or less and more preferred 10 µg or less. These dosage units are calculated on the basis of a normal patient with a weight of 75 kg. Typically, 1 to 10 dosage unit should be applied daily.

In one preferred embodiment the at least one substance (which is the active ingredient of the pharmaceutical composition of the present invention) is obtain-

- 6 -

able by hydrolysis of a protein. In a very preferred embodiment, the at least one substances is a peptide. The molecular weight of the peptide is preferably less than 30 kDa, more preferably less than 10 kDa. The at least one substance can be obtained by hydrolysis, especially suitable is a enzymatic hydrolysis and a  
5 very preferred enzyme is chymotrypsin.

Moreover, in a preferred embodiment, the at least one substance can bind to a heat shock protein (HSP).

10 In a further embodiment, the composition can comprise an "enhancer". Suitable enhancers are nucleoside triphosphates, nucleoside diphosphates, nucleoside monophosphates, nucleosides or analogs thereof, immunosuppressive cytokines, 1,25-dihydroxyvitamin D3 or analogs thereof, lipopolysaccharides, endotoxins heat shock proteins, thioredoxin with either NADPH and NADP-Thioredoxin re-  
15 ductase or dithiothreitol.

It is preferred that the pharmaceutical composition is free of heat shock proteins.

20 The composition of the present invention is especially useful for the treatment or prevention of graft rejection, allergic reaction or autoimmune disease. They are further suitable for eliciting oral tolerance and/or the induction of cells that may produce immunosuppressive cytokines, more preferably TGF-beta and/or IL-4 and/or IL-10.

25

In a further embodiment the invention provides a process for the preparation of the composition which comprises the steps of

- hydrolyzing an antigenic structure which induces graft rejection, allergic reac-  
30 tion or autoimmune disease to obtain at least one substance
- formulating the at least one substance for enteric or sublingual administration.

- 7 -

As explained above, hydrolysis can be an enzymatic hydrolysis and hydrolysis with chymotrypsin is especially preferred. The invention is explained in more details by the following examples.

## 5    **Examples**

Four groups of mice were sensitized against  $\beta$ -lactoglobulin (BLG) according to the following protocol.

### 10    *Chymotrypsin digestion*

One milligram of BLG is dissolved in 1 mL of Tris.HCL 40 mM, 10 mM  $\text{CaCl}_2$  pH 8.0 and 20  $\mu\text{L}$  of chymotrypsin solution (final ratio protein/protease of 0.2) is added to the protein. The resulting solution is incubated at 37°C for six hours.

15    The solution is then centrifuged through a centricon YM-10 assembly to remove the remaining protein and chymotrypsin.

### *HPLC analysis*

20    The low molecular weight fractions are fractionated by reverse phase high pressure liquid chromatography (HPLC) using a Vydac C18 reverse phase column (HP32, 201TP52 C18, 250/2.1 mm, 5  $\mu\text{m}$ ). The elution of the peptides can be monitored at both OD 214 nm and OD 280 nm.

25    Figure 1:    peptides (MW  $\leq$  10 kDa) generated by chymotrypsin-cleavage of BLB

Figure 2:    peptides from the chymotrypsin-cleavage of BLG (MW  $\leq$  10 kDa) that were bound to DnaK.

### 30    *DnaK.ATP preparation*

25  $\mu\text{L}$  of ATP solution (4.5 mg/mL) in buffer 1 (25 mM HEPES, 10 mM KCl, 3 mM

- 8 -

MgCl<sub>2</sub>, 5 mM 2-mercaptoethanol, pH 7.5) is added to 400 µL of DnaK (2 mg/mL of buffer 1). The solution is incubated at 20°C for one hour, and then is centrifuged through a centricon YM-10 assembly to remove any low molecular weight material loosely associated with Dna K. The large molecular weight fraction is removed, and washed extensively with buffer 1 by ultrafiltration using a centricon YM-10.

*In vitro production of the compositions*

- 10 The ultrafiltrated digestion is diluted in the suitable buffer 1. Then, ADP is added (1 mM final) and the mixture is incubated for one hour at 25°C

or the ultrafiltrated digestion is mixed with the ADP-pretreated DnaK. Then, ADP is added (1 mM final) and the mixture is incubated for one hour at 25°C in the suitable buffer 1.

Both types of compositions are further diluted in the suitable buffer 1 to give the following compositions (total doses):

- 20 p8: 10 µg hydrolyzed BLG + 10 µg HSP  
p9: 1 µg hydrolyzed BLG + 1 µg HSP  
p10: 10 µg hydrolyzed BLG  
p11: 1 µg hydrolyzed BLG  
c: control (buffer)

25 *Animal studies*

Four groups of mice were sensitized against BLG at days J0, J7, J14 and J21 by gavage after gastric incubation with 20 mg BLG and 10 µg cholera toxin in 0.2 M Na<sub>2</sub>HCO<sub>3</sub>.

The compositions are administered in 5 equivalent doses (total dose divided by

- 9 -

5) every two days from the first day of the treatment (J26).

Mice are individually treated, and oral administration is performed by buccal injection in micro-doses of 0.012 mL.

5

On day 36 and 56, immunoglobulines were measured

Figure 3 discloses the change of IgG1.

Figure 4 discloses results for IgE.

10 Figure 5 discloses results for IgG2a.

Figure 6 discloses results for IgA.

It can be seen that the animals treated with peptides free of HSP show a reduced augmentation of immunoglobulines. For IgE a composition comprising peptides alone is similar to the control group.

15

Figure 7 gives clinic scores for the different groups.

As can be seen from these data, some of the animals show a reduced clinical score when treated with small amount of a pharmaceutical composition of the present invention (1 µg; P 11) compared to a higher amount (10 µg; P10). This study also shows that significant oral tolerance was reached when the oral dose of peptides was lower than 10 µg. Low amounts of a pharmaceutical composition of the present invention seems to suppress the specific humoral response towards BLG (IgG1 and IgG2a) from days 36 to 56, whereas a pharmaceutical composition of the present invention combined with an adjuvant (HSP) induces an oral tolerance with stabilization of the IgG2a levels from days 36 to 56.

20

25

- 10 -

**Claims**

1. A pharmaceutical composition for sublingual or enteric administration comprising at least one substance obtainable by hydrolysis of an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease.  
5
2. The pharmaceutical composition of claim 1 wherein the amount of the at least one substance is in the range of 0,001 to 1000 µg, preferably 1 to 100 µg.
3. The pharmaceutical composition of claim 1 or 2 wherein the at least one  
10 substance is obtainable by hydrolysis of a protein.
4. The composition of any one of claim 1 to 3 wherein the at least one substance is a peptide.
5. The composition of claim 4 wherein the peptide has a molecular weight of less than 30 kDa, preferably less than 10 kDa.
- 15 6. The composition of any one of claim 1 to 5 wherein the hydrolysis is an enzymatic hydrolysis, preferably by chymotrypsin.
7. The composition of any one of claim 1 to 5 comprising additionally nucleoside triphosphates, nucleoside diphosphates, nucleoside monophosphates, nucleosides or analogs thereof, immunosuppressive cytokines, 1,25-  
20 dihydroxyvitamin D3 or analogs thereof, lipopolysaccharides, endotoxins, heat shock proteins.
8. The composition of any one of claim 1 to 7 wherein the antigenic structure is selected from insulin, thyroglobulin, thyroid peroxidase, type II collagen, gliadin, GAD65, proteolipid protein, S-antigen, acetylcholin receptor, haptenized colonic proteins, interphotoreceptor retinoid binding protein, myelin  
25

- 11 -

basic protein, myelin oligodendrocyte glycoprotein, peripheral nerve P2, cytoplasmic TSH receptor, intrinsic factor, lens proteins, platelets, nucleoproteins such as histones, heat shock proteins, MHC I, MHC II, MHC-peptides complexes, milk allergens, venom allergens, egg allergens, weed allergens, 5 grass allergens, tree allergens, shrub allergens, flower allergens, grain allergens, fungi allergens, fruit allergens, berry allergens, nut allergens, seed allergens, bean allergens fish allergens, shellfish allergens, meat allergens, spices allergens, insect allergens, mite allergens, animal allergens, animal dander allergens, allergens of Hevea brasiliensis, coagulation factors and 10 blood group antigens.

9. Use of the composition according to any one of claims 1 to 8 for the treatment or prevention of graft rejection, allergic reaction or autoimmune disease.


10. Use of a composition according to any one of claims 1 to 8 for eliciting oral 15 tolerance and/or the induction of cells that may produce immunosuppressive cytokines, more preferably TGF-beta and/or IL-4 and/or IL-10.

11. A process for the preparation of the composition of any one of claims 1 to 9 comprising the steps of

- 20 • hydrolyzing an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease to obtain at least one substance
- formulating the at least one substance for enteric or sublingual administration

- 1/7 -


Figure 1






- 2/7 -

Figure 2




- 3/7 -

Figure 3




- 4/7 -

Figure 4




- 5/7 -

Figure 5







- 6/7 -

Figure 6



- 7/7 -

Figure 7

**Challenge J36****Challenge J56**

Additional Sheet

**Representatives continued:**

Dipl.-Chem. Alek von Kreisler

Dipl.-Ing. Günther Selting

Dr. Hans-Karsten Werner

Dr. Johann F. Fues

Dipl.-Ing Georg Dallmeyer

Dipl.-Ing. Jochen Hilleringmann

Dr. Hans-Wilhelm Meyers

Dr. Hans-Peter Jönsson

Dr. Thomas Weber

Dr. Jörg Helbing

Dipl.-Ing Alexander von Kirschbaum

P.O. Box 10 22 41

D - 50462 Köln

- 12 -

**Abstract**

A pharmaceutical composition for sublingual or enteric administration comprising at least one substance obtainable by hydrolysis of an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease.

5